An observational study in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Intergroupe Francophone du Myelome · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome — 1 open to participants now, 4 under way, 2 of them phase 3. Multiple Myeloma · Intergroupe Francophone du Myelome.
Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, this one is the only one that started in 2022, is one of 3 observational ones, and was the 8th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →1 of the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome is open now, in 2 countries. Recruiting first, the newest first:
Intergroupe Francophone du Myelome · Sites in Belgium, France
Ages 18–69
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 205 across the 7 interventional studies, 180 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Intergroupe Francophone du Myelome is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
1 of the studies in Multiple Myeloma by Intergroupe Francophone du Myelome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06062537Intergroupe Francophone du MyelomeAnalysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.
To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients.
180 evaluable patients are required. For each of them, both spot urine sample and 24h urine sample will be collected at Cycle1 Day1, Cycle 2 Day 1 and Cycle 4 Day 1.
The detection of urine monoclonal component will be performed by urine protein electrophoresis (quantitative) and urine immunofixation (qualitative).
Patient with Multiple Myeloma whatever the line of treatment started in one of the twenty investigators sites located in France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision
Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit. Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit.
Diagnostic Test: Detection of monoclonal component
Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample
Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample compared to the reference measurement of 24 hours urine. Sensitivity is defined as the proportion, among the patients with positive urinalysis results on 24 hours urine, of positive results on spot urine sample. Evaluation is performed by urine protein electrophoresis and urine immunofixation
Time frame: at the first Day of Cycle n°2 (each cycle is 28 days or 21 days)
Evaluate the specificity of urine monoclonal component detection on spot urine sample
Evaluate the specificity of urine monoclonal component detection on sample at C2D1 compared to the reference measurement of 24 hours urine sample. Specificity is defined as the proportion, among patients with negative urinalysis results on 24 hours urine, of negative results on the spot urine sample.
Time frame: at the first Day of cycle n°2 (each cycle is 28 days or 21 days)
Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample
Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample at C1D1 and C4D1 compared to reference measurement of 24hours urine sample
Time frame: at the first day of cycle n°1 and cycle n°4 (each cycle is 28 days or 21 days)
Compare the responses rate
Compare the rate of partial responses, very good partial responses and complete responses (IMWG criteria) but only on the urinary monoclonal component) at C2D1 and C4D1 between the two types of samples (spot urine sample and 24hours urine sample)
Time frame: at the first day of cycle n° 2 and cycle 4 (each cycle is 28 days or 21 days)
Compare the monoclonal component / creatininuria ratios
Compare the monoclonal component / creatininuria ratios in both samples (spot urine sample and 24hours urine sample) for components monoclonal which are quantifiable in both types of urine samples
Time frame: at the first day of cycle n° 1,2 and 4
Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease)
Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease) at C1D1 and on the others points, if the monoclonal component is quantifiable)
Time frame: at the first day of cycle n° 1 (each cycle is 28 days or 21 days)
Assess the association between the rate of serum light chains and concentration of monoclonal components
To assess the association between serum light chains and concentration of monoclonal components for both types of urine samples.
Time frame: at first day of cycle 2 (each cycle is 28 days or 21 days)
Evaluate the urine monoclonal component by the difference between proteinuria and albuminuria
To Evaluate if the rate of urine monoclonal component (in g/L)could by calculated by the difference between proteinuria (in g/L) and albuminuria (in g/L)
Time frame: at first day of cycle 2 (each cycle is 28 days or 21 days)
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for May 2026, 48 months after the start.
Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 33. This study's planned 48 months is below that.
Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intergroupe Francophone du Myelome